Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses

John W. Smith, Edwin B. Walker, Bernard A. Fox, Daniel Haley, Ketura P. Wisner, Teri Doran, Brenda Fisher, Lisa Justice, William Wood, John Vetto, Holden Maecker, Annemiek Dols, Sybren Meijer, Hong Ming Hu, Pedro Romero, W. Gregory Alvord, Walter J. Urba

    Research output: Contribution to journalArticle

    98 Scopus citations

    Abstract

    Purpose: To measure the CD8+ T-cell response to a melanoma peptide vaccine and to compare an every-2-weeks with an every-3-weeks vaccination schedule. Patients and Methods: Thirty HLA-A2-positive patients with resected stage I to III melanoma were randomly assigned to receive vaccinations every 2 weeks (13 vaccines) or every 3 weeks (nine vaccines) for 6 months. The synthetic, modified gp100 peptide, g209-2M, and a control peptide, HPV16 E7, were mixed in incomplete Freund's adjuvant and injected subcutaneously. Peripheral blood mononuclear cells obtained before and after vaccination by leukapheresis were analyzed using a fluorescence-based HLA/peptide-tetramer binding assay and cytokine flow cytometry. Results: Vaccination induced an increase in peptide-specific T cells in 28 of 29 patients. The median frequency of CD8+ T cells specific for the g209-2M peptide increased markedly from 0.02% before to 0.34% after vaccination (P < .0001). Eight patients (28%) exhibited peptide-specific CD8+ T-cell frequencies greater than 1%, including two patients with frequencies of 4.96% and 8.86%, respectively. Interferon alfa-2b-treated patients also had significant increases in tetramer-binding cells (P < .0001). No difference was observed between the every-2-weeks and the every-3-weeks vaccination schedules (P = .59). Conclusion: Flow cytometric analysis of HLA/peptide-tetramer binding cells was a reliable means of quantifying the CD8+ T-cell response to peptide immunization. This assay may be suitable for use in future trials to optimize different vaccination strategies. Concurrent interferon treatment did not inhibit the development of a peptide-specific immune response and vaccination every 2 weeks, and every 3 weeks produced similar results.

    Original languageEnglish (US)
    Pages (from-to)1562-1573
    Number of pages12
    JournalJournal of Clinical Oncology
    Volume21
    Issue number8
    DOIs
    StatePublished - Apr 15 2003

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8<sup>+</sup> T-cell responses'. Together they form a unique fingerprint.

  • Cite this

    Smith, J. W., Walker, E. B., Fox, B. A., Haley, D., Wisner, K. P., Doran, T., Fisher, B., Justice, L., Wood, W., Vetto, J., Maecker, H., Dols, A., Meijer, S., Hu, H. M., Romero, P., Alvord, W. G., & Urba, W. J. (2003). Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. Journal of Clinical Oncology, 21(8), 1562-1573. https://doi.org/10.1200/JCO.2003.09.020